Prospective study of Foscarnet sodium administration for the prevention of HHV-6 encephalitis after hematopoietic stem cell transplantation

Prospective study of Foscarnet sodium administration for the prevention of HHV-6 encephalitis after hematopoietic stem cell transplantation - Preemptive therapy with Foscarnet for the prevention of HHV-6 encephalitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001346

Enrollment

Registered

2008-08-30

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hematologic malignancies, transplanted unrelated cord blood (UCBT) or HLA-one haplotype mismatch graft from a relative (haplo SCT)

Interventions

We measure the amount of HHV-6 DNA in plasma triweekly. When the amount of HHV-6 DNA excess 5x10e2 copy/ml, we start PFA administration 90mg/kg/day and continue the measurement triweekly. In case the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hematologic disease who are transplanted unrelated cord blood or HLA-haploidentical hematopoietic stem cell from a relative.

Exclusion criteria

Exclusion criteria: 1. Hypersensitive for PFA 2. Existence of comorbid disease, grade 3 or more in CTCAE v3.0 (except renal insufficiency) 3. Existence of renal insufficiency, grade 2 or more in CTCAE v3.0 4. Unsuitable for enrollment judged by attending physian

Design outcomes

Primary

Measure	Time frame
Frequency of adverse event caused by PFA administration by day 35 after SCT.	—

Secondary

Measure	Time frame
1. Change of plasma HHV-6 DNA after PFA administration by day 35 after SCT. 2. Preventive effect of PFA administration by day 35 after SCT.	—

Countries

Japan

Contacts

Public ContactISHIYAMA, Ken

Graduate School of Medical Science, Kanazawa University Cellular transplantation biology

ishiyamak@med3.m.kanazawa-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026